Neonatal Treatment Articles & Analysis

1 news found

Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

Pharmacologic treatment for these neonates is limited to caffeine (methylxanthines), the most widely used first-line treatment option. ...

Aug. 9, 2022

ByEnalare Therapeutics Inc.

Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you